We are live on ! Find out more
PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

60 hedge funds and large institutions have $84.3M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

38% more capital invested

Capital invested by funds: $61.1M → $84.3M (+$23.2M)

29% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 14

20% more funds holding

Funds holding: 50 → 60 (+10)

13% more call options, than puts

Call options by funds: $89K | Put options by funds: $79K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
60
Holders Change
+10
Holders Change %
+20%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
19
Increased
18
Reduced
14
Closed
9
Calls
$89K
Puts
$79K
Net Calls
+$10K
Net Calls Change
+$10K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$409K
2
Ameriprise
Ameriprise
Minnesota
+$391K
3
Morgan Stanley
Morgan Stanley
New York
+$337K
4
Millennium Management
Millennium Management
New York
+$270K
5
AllianceBernstein
AllianceBernstein
Tennessee
+$193K

Top Sellers

Rank Fund Capital Flow
1
GTC
Ghost Tree Capital
New York
-$1.65M
2
FCM
Farallon Capital Management
California
-$280K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$247K
4
Renaissance Technologies
Renaissance Technologies
New York
-$140K
5
BCM
Bridgeway Capital Management
Texas
-$137K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$30.6M – – –
Wellington Management Group
2
Wellington Management Group
Massachusetts
$18.5M -$49K -11,055 -0.3%
JJIJ
3
Johnson & Johnson Innovation - JJDC
New Jersey
$7.39M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$5.26M +$83.8K +18,925 +2%
BlackRock
5
BlackRock
New York
$4.98M +$409K +92,379 +9%
Vanguard Group
6
Vanguard Group
Pennsylvania
$3.39M -$3.65K -825 -0.1%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$2.46M -$247K -55,768 -9%
DCM
8
DAFNA Capital Management
California
$1.47M – – –
State Street
9
State Street
Massachusetts
$1.19M +$38.9K +8,773 +4%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$1.04M +$49.9K +11,275 +5%
Stifel Financial
11
Stifel Financial
Missouri
$815K -$3.02K -682 -0.4%
Northern Trust
12
Northern Trust
Illinois
$766K -$19.7K -4,458 -3%
Morgan Stanley
13
Morgan Stanley
New York
$743K +$337K +76,053 +89%
Millennium Management
14
Millennium Management
New York
$734K +$270K +61,025 +62%
BCM
15
Bridgeway Capital Management
Texas
$702K -$137K -30,900 -17%
Renaissance Technologies
16
Renaissance Technologies
New York
$605K -$140K -31,700 -19%
Ameriprise
17
Ameriprise
Minnesota
$406K +$391K +88,346 New
SM
18
Sabby Management
Florida
$354K -$136K -30,607 -28%
PTP
19
Platform Technology Partners
New York
$248K +$85.1K +19,224 +55%
AllianceBernstein
20
AllianceBernstein
Tennessee
$200K +$193K +43,500 New
Charles Schwab
21
Charles Schwab
California
$187K +$17K +3,849 +10%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$182K -$6.62K -1,495 -4%
Dimensional Fund Advisors
23
Dimensional Fund Advisors
Texas
$181K +$174K +39,348 New
BBP
24
Banco BTG Pactual
Brazil
$154K +$148K +33,500 New
N
25
Nuveen
North Carolina
$149K -$44.9K -10,146 -24%
1
2 3

PHAS Hedge Fund Activity: Q2 2020 in Review

60 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q2 2020, worth a combined $84.3M — up 38% from $61.1M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new PHAS positions and 9 closed out — a net gain of 10 holders — while 18 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $409K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $1.65M sold.

  • 60 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q2 2020, up from 50 in Q1 2020.
  • Funds reported $84.3M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q2 2020, up 38% quarter-over-quarter.
  • 19 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 9 closed out, a net change of +10 holders.
  • The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $409K added.
  • The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was Ghost Tree Capital, an estimated $1.65M sold.

Based on aggregated 13F filings for Q2 2020.